Loading…
DCTH
Delcath Systems Inc
NASDAQ· Healthcare· Medical Devices
$16.34-0.31%
Key metrics
- Market cap
- $566.98M
- P/E
- 1634.0x
- Forward P/E
- 363.1x
- P/B
- 4.7x
- Dividend yield
- —
- EPS
- $0.01
- ROE
- 0.47%
- Profit margin
- 0.56%
- Revenue growth
- +20.60%
- Beta
- 0.52
- 52-week high
- $17.42
- 52-week low
- $8.12
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
- 156
- Queensbury, United States
Company description provided by Yahoo Finance.